Takeuchi Takuro, Inoue Akira, Nishizawa Yujiro, Kagawa Yoshinori, Aomatsu Michihiro, Tsuji Yoshito, Hirano Masataka, Komatsu Hisateru, Tomokuni Akira, Miyazaki Yasuhiro, Motoori Masaaki, Fushimi Hiroaki, Iwase Kazuhiro, Gotoh Mitsukazu, Fujitani Kazumasa
Dept. of Gastroenterological Surgery, Osaka General Medical Center.
Gan To Kagaku Ryoho. 2021 Dec;48(13):2133-2135.
In Japan, the standard treatment for squamous cell anal cancer(SCAC)has not been established. Herein, we report a case of SCAC that completely responded to chemoradiotherapy(CRT).
A woman in her 80s presented with anal pain and bleeding. Computed tomography revealed bilateral inguinal adenopathy and a tumor in the anal canal. Histopathological examination of endoscopic biopsies showed adenocarcinoma. Thus, she was diagnosed with anal canal adenocarcinoma and lymph node metastases:cT3, cN1a(No. 292), cM0, cStage Ⅲc(Japanese Classification of Colorectal, Appendiceal, and Anal Carcinoma, 9th edition). Owing to her advanced age and refusal of a stoma, CRT(S-1, mitomycin C, and radiotherapy)was administered with the expectation that salvage surgery in the form of rectal amputation would eventually be necessary. The tumor noticeably shrank after CRT. The patient is alive to this date,14 months after the final round of CRT.
在日本,鳞状细胞肛管癌(SCAC)的标准治疗方法尚未确立。在此,我们报告一例对放化疗(CRT)完全缓解的SCAC病例。
一名80多岁的女性出现肛门疼痛和出血。计算机断层扫描显示双侧腹股沟淋巴结肿大以及肛管内有肿瘤。内镜活检的组织病理学检查显示为腺癌。因此,她被诊断为肛管腺癌伴淋巴结转移:cT3,cN1a(292号),cM0,cⅢc期(日本结直肠癌、阑尾癌和肛管癌分类,第9版)。由于她年事已高且拒绝造口,给予了放化疗(S-1、丝裂霉素C和放疗)治疗,预计最终可能需要进行直肠截肢等挽救性手术。放化疗后肿瘤明显缩小。截至目前,在最后一轮放化疗后14个月,该患者仍然存活。